● TIER 3 — Information onlyGRADE BGH secretagogues & GH axis
CJC-1295
GHRH analog (DAC). Research verification: Yes (TGA pending). 1 human study record(s) in the FitClinicMD studies database.
GOALS · Muscle / body composition
FDA status
Not approved.
Compounding (503A/503B)
Listed by FDA under 'nominated but withdrawn' from Category 2 (i.e., no longer in Category 2, but NOT on the 503A bulks list or Category 1) — (FDA cited increased heart rate, vasodilatory reactions).
DEA
Not controlled.
WADA (sport)
S2.2.4 GH-releasing factors: GHRH & analogues (CJC-1295, sermorelin, tesamorelin), GHS (ibutamoren, ipamorelin), GHRPs (GHRP-2/6, hexarelin)
Mechanism
Albumin-binding GHRH; t½ ~6-8 d.
Human evidence · 1
Phase 1 healthy adults: sustained GH/IGF-1 elevation. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Reference only. This page summarizes publicly available regulatory and research information about CJC-1295. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.